Wall Street brokerages expect MannKind Co. (NASDAQ:MNKD – Get Rating) to post $15.54 million in sales for the current fiscal quarter, according to Zacks Investment Research. Three analysts have made estimates for MannKind’s earnings, with the highest sales estimate coming in at $16.40 million and the lowest estimate coming in at $14.22 million. MannKind reported […]
Read the latest stock market news on MarketBeat. Get real-time analyst ratings, dividend information, earnings results, financials, headlines, insider trades and options data for any stock.
MannKind (NASDAQ:MNKD – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Wednesday, Zacks.com reports. According to Zacks, “Mannkind Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases such as […]
National Bank of Canada FI acquired a new stake in shares of MannKind Co. (NASDAQ:MNKD – Get Rating) during the 4th quarter, HoldingsChannel.com reports. The institutional investor acquired 23,270 shares of the biopharmaceutical company’s stock, valued at approximately $101,000. Several other institutional investors also recently bought and sold shares of MNKD. Emerald Advisers LLC raised […]
StockNews.com upgraded shares of MannKind (NASDAQ:MNKD – Get Rating) to a sell rating in a research note published on Thursday. MNKD has been the subject of several other research reports. HC Wainwright lowered their price target on MannKind from $6.50 to $6.00 and set a buy rating for the company in a report on Monday, […]